CFM
ANIX icon

Catalyst Funds Management’s Anixa Biosciences ANIX Stock Holding History

Catalyst Funds Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,300
Closed -$31.7K – 660
2026
Q1 		$31.7K Buy
+12,300
New +$36.4K 0.01% 561

Other funds holding ANIX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Catalyst Funds Management's ANIX Position: Q2 2026 in Review

Catalyst Funds Management sold out of Anixa Biosciences (ANIX) in Q2 2026, closing a stake of 12,300 shares — an estimated $31.7K sold.

Catalyst Funds Management first reported a position in ANIX in Q1 2026 and held it in 1 quarter. The position peaked at $31.7K in Q1 2026. 62 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Catalyst Funds Management reported no remaining Anixa Biosciences position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 12,300 Anixa Biosciences shares in Q2 2026, an estimated $31.7K.
  • Catalyst Funds Management first reported a position in Anixa Biosciences in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's Anixa Biosciences position peaked at $31.7K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.